Impact of plasma-wall interaction and exhaust on the EU-DEMO design

In the present work, the role of plasma facing components protection in driving the EU-DEMO design will be reviewed, focusing on steady-state and, especially, on transients. This work encompasses both the first wall (FW) as well as the divertor. In fact, while the ITER divertor heat removal technology has been adopted, the ITER FW concept has been shown in the past years to be inadequate for EU-DEMO. This is due to the higher foreseen irradiation damage level, which requires structural materials (like Eurofer) able to withstand more than 5 dpa of neutron damage. This solution, however, limits the tolerable steady-state heat flux to ~1 MW/m2, i.e. a factor 3–4 below the ITER specifications. For this reason, poloidally and toroidally discontinuous protection limiters are implemented in EU-DEMO. Their role consists in reducing the heat load on the FW due to charged particles, during steady state and, more importantly, during planned and off-normal plasma transients. Concerning the divertor configuration, EU-DEMO currently assumes an ITER-like, lower single null (LSN) divertor, with seeded impurities for the dissipation of the power. However, this concept has been shown by numerous simulations in the past years to be marginal during steady-state (where a detached divertor is necessary to maintain the heat flux below the technological limit and to avoid excessive erosion) and unable to withstand some relevant transients, such as large ELMs and accidental loss of detachment. Various concepts, deviating from the ITER design, are currently under investigation to mitigate such risks, for example in-vessel coils for strike point sweeping in case of reattachment, as well as alternative divertor configurations. Finally, a broader discussion on the impact of divertor protection on the overall machine design is presented

Comparing serial X-ray crystallography and microcrystal electron diffraction (MicroED) as methods for routine structure determination from small macromolecular crystals.

Innovative new crystallographic methods are facilitating structural studies from ever smaller crystals of biological macromolecules. In particular, serial X-ray crystallography and microcrystal electron diffraction (MicroED) have emerged as useful methods for obtaining structural information from crystals on the nanometre to micrometre scale. Despite the utility of these methods, their implementation can often be difficult, as they present many challenges that are not encountered in traditional macromolecular crystallography experiments. Here, XFEL serial crystallography experiments and MicroED experiments using batch-grown microcrystals of the enzyme cyclophilin A are described. The results provide a roadmap for researchers hoping to design macromolecular microcrystallography experiments, and they highlight the strengths and weaknesses of the two methods. Specifically, we focus on how the different physical conditions imposed by the sample-preparation and delivery methods required for each type of experiment affect the crystal structure of the enzyme

O(N) methods in electronic structure calculations

Linear scaling methods, or O(N) methods, have computational and memory requirements which scale linearly with the number of atoms in the system, N, in contrast to standard approaches which scale with the cube of the number of atoms. These methods, which rely on the short-ranged nature of electronic structure, will allow accurate, ab initio simulations of systems of unprecedented size. The theory behind the locality of electronic structure is described and related to physical properties of systems to be modelled, along with a survey of recent developments in real-space methods which are important for efficient use of high performance computers. The linear scaling methods proposed to date can be divided into seven different areas, and the applicability, efficiency and advantages of the methods proposed in these areas is then discussed. The applications of linear scaling methods, as well as the implementations available as computer programs, are considered. Finally, the prospects for and the challenges facing linear scaling methods are discussed.Comment: 85 pages, 15 figures, 488 references. Resubmitted to Rep. Prog. Phys (small changes

AAV-Mediated Gene Supplementation Therapy in Achromatopsia Type 2: Preclinical Data on Therapeutic Time Window and Long-Term Effects

Achromatopsia type 2 (ACHM2) is a severe, inherited eye disease caused by mutations in the CNGA3 gene encoding the a subunit of the cone photoreceptor cyclic nucleotide-gated (CNG) channel. Patients suffer from strongly impaired daylight vision, photophobia, nystagmus, and lack of color discrimination. We have previously shown in the Cnga3 knockout (KO) mouse model of ACHM2 that gene supplementation therapy is effective in rescuing cone function and morphology and delaying cone degeneration. In our preclinical approach, we use recombinant adeno-associated virus (AAV) vector-mediated gene transfer to express the murine Cnga3 gene under control of the mouse blue opsin promoter. Here, we provide novel data on the efficiency and permanence of such gene supplementation therapy in Cnga3 KO mice. Specifically, we compare the influence of two different AAV vector capsids, AAV2/5 (Y719F) and AAV2/8 (Y733F), on restoration of cone function, and assess the effect of age at time of treatment on the long-term outcome. The evaluation included in vivo analysis of retinal function using electroretinography (ERG) and immunohistochemical analysis of vector-driven Cnga3 transgene expression. We found that both vector capsid serotypes led to a comparable rescue of cone function over the observation period between 4 weeks and 3 months post treatment. In addition, a clear therapeutic effect was present in mice treated at 2 weeks of age as well as in mice treated at 3 months of age at the first assessment at 4 weeks after treatment. Importantly, the effect extended in both cases over the entire observation period of 12 months post treatment. However, the average ERG amplitude levels differed between the two groups, suggesting a role of the absolute age, or possibly, the associated state of the degeneration, on the achievable outcome. In summary, we found that the therapeutic time window of opportunity for AAV-mediated Cnga3 gene supplementation therapy in the Cnga3 KO mouse model extends at least to an age of 3 months, but is presumably limited by the condition, number and topographical distribution of remaining cones at the time of treatment. No impact of the choice of capsid on the therapeutic success was detected

Development of a concept and basis for the DEMO diagnostic and control system

An initial concept for the plasma diagnostic and control (D&C) system has been developed as part of European studies towards the development of a demonstration tokamak fusion reactor (DEMO). The main objective is to develop a feasible, integrated concept design of the DEMO D&C system that can provide reliable plasma control and high performance (electricity output) over extended periods of operation. While the fusion power is maximized when operating near to the operational limits of the tokamak, the reliability of operation typically improves when choosing parameters significantly distant from these limits. In addition to these conflicting requirements, the D&C development has to cope with strong adverse effects acting on all in vessel components on DEMO (harsh neutron environment, particle fluxes, temperatures, electromagnetic forces, etc.). Moreover, space allocation and plasma access are constrained by the needs for first wall integrity and optimization of tritium breeding. Taking into account these boundary conditions, the main DEMO plasma control issues have been formulated, and a list of diagnostic systems and channels needed for plasma control has been developed, which were selected for their robustness and the required coverage of control issues. For a validation and refinement of this concept, simulation tools are being refined and applied for equilibrium, kinetic and mode control studies

Progress in EU-DEMO in-vessel components integration

In the EU DEMO design (Romanelli, 2012; Federici et al., 2014), due to the large number of complex systems inside the tokamak vessel it is of vital importance to address the in-vessel integration at an early stage in the design process. In the EU DEMO design, after a first phase in which the different systems have been developed independently based on the defined baseline DEMO configuration, an effort has been made to define the interface requirements and to propose the strategies for the mechanical integration of the auxiliary heating and fuelling systems into the Vacuum Vessel and the Breeding Blanket. This work presents the options studied, the engineering solutions proposed, and the issues highlighted for the mechanical in-vessel integration of the DEMO fuelling lines, auxiliaries heating systems, and diagnostics